Zobrazeno 1 - 10 of 14 pro vyhledávání: '"Heidrun Degen"'
1
Akademický článek
ADPase CD39 Fused to Glycoprotein VI‐Fc Boosts Local Antithrombotic Effects at Vascular Lesions
Autor: Heidrun Degen, Oliver Borst, Melanie Ziegler, Ann‐Katrin Mojica Munoz, Janina Jamasbi, Britta Walker, Silvia Göbel, Julia Fassbender, Kristin Adler, Richard Brandl, Götz Münch, Reinhard Lorenz, Wolfgang Siess, Meinrad Gawaz, Martin Ungerer
Publikováno v: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 6, Iss 8 (2017)
BackgroundGPVI (Glycoprotein VI) is the essential platelet collagen receptor in atherothrombosis. Dimeric GPVI‐Fc (Revacept) binds to GPVI binding sites on plaque collagen. As expected, it did not increase bleeding in clinical studies. GPVI‐Fc is
Externí odkaz: https://doaj.org/article/8c41f738c98d45e59044b26e25dfec32
Zobrazit plný text záznamu
2
Akademický článek
The GPVI-Fc fusion protein Revacept improves cerebral infarct volume and functional outcome in stroke.
Autor: Silvia Goebel, Zhongmin Li, Jasmin Vogelmann, Hans-Peter Holthoff, Heidrun Degen, Dirk M Hermann, Meinrad Gawaz, Martin Ungerer, Götz Münch
Publikováno v: PLoS ONE, Vol 8, Iss 7, p e66960 (2013)
OBJECTIVES: We examined the effect of Revacept, an Fc fusion protein which is specifically linked to the extracellular domain of glycoprotein VI (GPVI), on thrombus formation after vessel wall injury and on experimental stroke in mice. BACKGROUND: Se
Externí odkaz: https://doaj.org/article/937b3af4b40a4cc6996c43a0a8fe2f9b
Zobrazit plný text záznamu
6
Thyrotropin Receptor-Specific Lymphocytes in Adenovirus-TSHR-Immunized Native and Human Leukocyte Antigen-DR3-Transgenic Mice and in Graves' Disease Patient Blood
Autor: Heidrun Degen, Ioannis Gavvovidis, Thomas Blankenstein, Martin Ungerer, Kerstin Uhland
Publikováno v: Thyroid. 31:950-963
Background: Antigen-specific lymphocytes are increasingly investigated in autoimmune diseases and immune therapies. We sought to identify thyrotropin receptor (TSHR)-specific lymphocytes in mouse m...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e47b19992bf531734059dbd5249a9df
https://doi.org/10.1089/thy.2020.0338
Zobrazit plný text záznamu
7
Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation
Autor: Kerstin Uhland, Reinhard Lorenz, Götz Münch, Christian Weber, Richard Brandl, Heidrun Degen, Janina Jamasbi, Martin Ungerer, Remco T. A. Megens, Ann‐Katrin Mojica Munoz, Wolfgang Siess
Publikováno v: Thrombosis and Haemostasis, 117(8), 1651-1659. Georg Thieme Verlag
SummaryThe efficiency of current dual antiplatelet therapy might be further improved by its combination with a glycoprotein (GP) VI-targeting strategy without increasing bleeding. GPVI-Fc, a recombinant dimeric fusion protein binding to plaque collag
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1790d02d1755830941bfb7c132df49d2
https://doi.org/10.1160/th16-11-0856
Zobrazit plný text záznamu
8
ADPase CD39 Fused to Glycoprotein VI‐Fc Boosts Local Antithrombotic Effects at Vascular Lesions
Autor: Melanie Ziegler, Götz Münch, Meinrad Gawaz, Britta Walker, Julia Fassbender, Richard Brandl, Kristin Adler, Ann‐Katrin Mojica Munoz, Wolfgang Siess, Oliver Borst, Heidrun Degen, Martin Ungerer, Silvia Göbel, Reinhard Lorenz, Janina Jamasbi
Publikováno v: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background GPVI (Glycoprotein VI) is the essential platelet collagen receptor in atherothrombosis. Dimeric GPVI ‐Fc (Revacept) binds to GPVI binding sites on plaque collagen. As expected, it did not increase bleeding in clinical studies. GPVI ‐Fc
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cfd4f5ce44abd9f7d8f5ad0f7c26512
https://doi.org/10.1161/jaha.117.005991
Zobrazit plný text záznamu
9
Administration of the cyclic peptide COR‐1 in humans (phase I study): ex vivo measurements of anti‐β 1 ‐adrenergic receptor antibody neutralization and of immune parameters
Autor: Valérie Boivin-Jahns, Kristin Adler, Götz Münch, Martin J. Lohse, Martin Ungerer, Hans-Peter Holthoff, Mariola Lappo, Roland Jahns, Heidrun Degen, Stephan Truöl, Nina Steiger
Publikováno v: European Journal of Heart Failure. 14:1230-1239
Aims A novel concept for the treatment of heart failure is the neutralization of antibodies against the β1-adrenergic receptor (anti-β1AR-ab). In a rat model of autoimmune cardiomyopathy, the cyclic peptide COR-1 (given i.v. once monthly) neutraliz
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1d2ff8582280c8e6e1caf2cbd17896b
https://doi.org/10.1093/eurjhf/hfs118
Zobrazit plný text záznamu
10
Proteomic Characterization of the Angiogenesis Inhibitor SU6668 Reveals Multiple Impacts on Cellular Kinase Signaling
Autor: Axel Ullrich, György Kéri, Laszlo Orfi, Klaus Godl, Zoltán Horváth, Heidrun Degen, Martina Weber, Matthew Cotten, Oliver J. Gruss, Stefan Müller, Henrik Daub, Dirk Brehmer, Jan Eickhoff, Josef Wissing, Stephanie Blencke
Publikováno v: Cancer Research. 65:6919-6926
Knowledge about molecular drug action is critical for the development of protein kinase inhibitors for cancer therapy. Here, we establish a chemical proteomic approach to profile the anticancer drug SU6668, which was originally designed as a selectiv
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7618496dc39260436c2476ab54259afc
https://doi.org/10.1158/0008-5472.can-05-0574
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje